UNSPSC 51343512: Tenofovir disoproxil fumarate

This classification denotes a reverse transcriptase inhibitor with the molecular formula C19H30N5O10P.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTT9J7900I, chemically known as phosphonic acid, ((2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, (r)- but more generally known as tenofovir disoproxil fumarate, which bears US NIH Compound Identifier 464205. European Medicines Agency schedules Tenofovir disoproxil fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12607MIG.

UNSPSC 51343512 Tenofovir disoproxil fumarate is a Commodity code intended to classify a specific antiretroviral pharmaceutical product, but the recent state and local procurement activity posted under this code does not reflect purchases of tenofovir disoproxil fumarate itself. Instead, the tagged opportunities show pharmaceutical supply and emergency health-response procurement—naloxone distribution, drug deactivation systems, and broad-spectrum antibiotics—indicating a significant mismatch between the code's nominal scope and what agencies are actually buying under it in practice.

The geographic reach of tagged activity spans at least Florida and Illinois, though the sample is too small and misaligned to establish reliable regional concentration. Seminole County, Florida released an IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually (due Jul 26, 2023, with quarterly deliveries to Sanford), and the Illinois Department of Public Health awarded a piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (total award $2,999,999.11 over 12 months with two renewal options, completed August 28, 2026). Neither opportunity aligns with tenofovir disoproxil fumarate procurement. The code shows little relevant recent activity for the specific product it names; vendors pursuing state and local opportunities under this code should verify actual scope before responding, as the tagging appears to be either misconfiguration or a catch-all for pharmaceutical categories that do not map cleanly to narrower commodity codes.